Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population

Journal of Neuroimmunology

Volumn 236, Issue 1-2, 2011, Pages 87-92

  Mirowska Guzel, Dagmara ^a,b   Gromadzka, Grazyna ^a,b   Mach, Anna ^c   Czlonkowski, Andrzej ^b   Czlonkowska, Anna ^a,b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c Central Medical Hospital MSWiA   (Poland)

Author keywords

Cytokines; Disability; Multiple sclerosis; PCR; Single nucleotide polymorphism; Susceptibility

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; FEMALE; GENE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOTE; HUMAN; INTERLEUKIN 10 GENE; INTERLEUKIN 1A GENE; INTERLEUKIN 1B GENE; INTERLEUKIN 6 GENE; INTERLEUKIN RECEPTOR ANTAGONIST GENE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POLAND; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR NECROSIS FACTOR ALPHA GENE; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLAND; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960192091     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.04.014     Document Type: Article

References (49)

1. Aggelakis K., Zacharaki F., Dardiotis E., Xiromerisiou G., Tsimourtou V., Ralli S., Gkaraveli M., Bourpoulas D., Rodopoulou P., Papadimitriou A., Hadjigeorgiou G. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurol. Sci. 2010, 31:253.
2. Akcali A., Pehlivan S., Pehlivan M., Sever T., Akgul P., Neyal M. TNF-α promoter polymorphisms in multiple sclersois: no association with -308 and - 238 alleles, but the -857 alleles is associated with the disease in Turkish patients. Int. J. Immunogenet. 2010, 37:91-95.
3. Albani D., Batelli S., Polito L., Prato F., Pesaresi M., Gajo G.B., De Angeli S., Zanarado A., Galimberti D., Scarpini E., Galluci M., Forloni G. Interleukin-6 plasma level increase with age in an Italian eldery population ("The Treviso Longeva" - Trelong-study) with a sex-specific contribution of rs18000795 polymorphism. Age 2009, 31:155-162.
4. Arend W.P. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J. Clin. Invest. 1991, 88:1445-1451.
5. Armirzargar A., Khosravi F., Dianat S., Hushmand F., Maryousef P., Foroshani A.R., Lotfi J., Nikbin B. Profile of cytokine gene polymorphisms in Iranian multiple sclerosis patients. Mult. Scler. 2007, 13:253-255.
6. Azarpira N., Haghighi A.B., Pourjafar M., Shariat A. Interleukin 10 gene polymorphism in Iranian patients with multiple sclerosis. Acta Neurol. Taiwan. 2010, 19:107-111.
7. Bhojak T.J., DeKosky S.T., Ganguli M., Kamboh M.I. Genetic polymorphisms in the cathespin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci. Lett. 2000, 288:21-24.
8. Bongioanni P., Mosti S., Romano M.R., Lombardo F., Moscato G., Meucci G. Increased T-lymphocyte interleukin-6 binding in patients with multiple sclerosis. Eur. J. Neurol. 2000, 7:291-297.
9. Borzani T., Tola M.R., Caniatti L., Collins A., De Santis G., Luiselli D., Mamolini E., Scapoli C. The interleukin-1 cluster gene region is associated with multiple sclerosis in an Italian Caucasian population. Eur. J. Neurol. 2010, 17:930-938.
10. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37:424-435.
11. Daumer M., Neuhaus A., Herbert J., Ebers G. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision. J. Neurol. Sci. 2009, 287(suppl. 1):S50-S55.
12. De la Concha E.G., Arroyo R., Crusius J.B., Campillo J.A., Martin C., VarelaDeSeijas E., Pena A.S., Claveria L.E., Fernandez-Arquero M. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing-remitting multiple sclerosis. J. Neuroimmunol. 1997, 80:172-178.
13. Dinarello Ch.A. The interleukin-1 family: 10years of discovery. FASEB J. 1994, 8:1314-1325.
14. Dincić E., Zivković M., Stanković A., Obradović D., Alavantić D., Kostić V., Raicević R. Association of polymorphisms in CTLA-4, IL-1RA and IL-1beta genes with multiple sclerosis in Serbian population. J. Neuroimmunol. 2006, 177:146-150.
15. Drulović J., Popadić D., Mesaros S., Dujmović I., Cvetković I., Miljković D., Stojsavljević N., Pravica V., Pekmezović T., Bogdanović G., Jerebinski M., Mostarica Stojković M. Decreased frequency of the tumor necrosis factor alpha-308 allele in Serbian patients with multiple sclerosis. Eur. Neurol. 2003, 50:25-29.
16. Feakes R., Sawcer S., Broadley S., Coraddu F., Roxburg R., Gray J., Clayton D., Compston A. Interleukin-1 receptor antagonist (IL-1ra) in multiple sclerosis. J. Neuroimmunol. 2000, 105:96-101.
17. Fishman D., Faulds G., Jeffrey R., Mohamed-Ali V., Yudkin J.S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102:1369-1376.
18. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
19. Hellings N., Raus J., Stinissen P. Insights into the immunopathogenesis of multiple sclerosis. Immunol. Res. 2002, 25:27-51.
20. Huang D., Zheng Ch., Giscombe R., Matell G., Pirskanen R., Lefvert A.K. Polymorphisms at y174 and in the 3X flanking region of interleukin-6_IL-6/gene in patients with myasthenia gravis. J. Neuroimmunol. 1999, 101:197-200.
21. Huang S.L., Su C.H., Chang S.C. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am. J. Respir. Crit. Care Med. 1997, 156:1436-1439.
22. Huang W.X., He B., Hillert J. An interleukin-1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis. J. Neuroimmunol. 1996, 67:143-144.
23. Kamali-Sarvestani E., Nikseresht A., Flaki E., Sarvari J., Gharesi-Fard B. TNF-α, TNF-β and IL-4 gene polymorphism in Iranian patients with multiple sclerosis. Acta Neurol. Scand. 2007, 115:161-166.
24. Kantarci O.H., Atkinson E.J., Hebrink D.D., McMurray C.T., Weinshenker B.G. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J. Neuroimmunol. 2000, 106:220-227.
25. Kimura A., Kishimoto T. IL-6 regulator of Treg/Th17 balance. Eur. J. Immunol. 2010, 40:1830-1835.
26. Kiszel P., Makó V., Prohászka Z., Cervenak L. Interleukin-6-174 promoter polymorphism does not influence IL-6 production after LPS and IL-1Zβ stimulation in human umbilical cord vein endothelial cells. Cytokine 2007, 40:17-22.
27. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
28. Lang N.P., Tonetti M.S., Suter J., Sorrell J., Duff G.W., Kornman K.S. Effect of interleukin-1 gene polymorphisms on gingival inflammation assessed by bleeding on probing in a periodontal maintenance population. J. Periodontal Res. 2000, 35:102-107.
29. Lowe P.R., Galley H.F. A novel PCR-RFLP assay for the detection of the single nucleotide polymorphism at position -1082 in the human IL-10 gene promoter. Eur. J. Immunogenet. 2001, 28:563-564.
30. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911. for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
31. Malmeström C., Andersson B.A., Haghighi S., Lycke J. IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implication for their possible immunopathogenic role. J. Neuroimmunol. 2006, 175:176-182.
32. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121.
33. Mihailova S., Ivanova M., Mihaylova A., Quin L., Mikova O., Naumova E. Pro- and anti-infalmmatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. J. Neuroimmunol. 2005, 168:138-143.
34. Nishimura M., Mizuta I., Mizuta E., Yamasaki S., Ohta M., Kuno S. Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease. Neurosci. Lett. 2000, 284:73-76.
35. Okuda Y., Sakoda S., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glycoprotein 35-55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1999, 101:188-196.
36. Okuda Y., Sakoda S., Saeki Y., Kishimoto T., Yanagihara T. Enhancement of Th2 response in IL-6-deficient mice immunized with myelin oligodendrocyte glycoprotein. J. Neuroimmunol. 2000, 105:120-123.
37. Pickard C., Mann C., Sinnott P., Boggild M., Hawkins C., Strange R.C., Hutchinson I.V., Ollier W.E.R., Donn R.P. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. J. Neuroimmunol. 1999, 101:207-210.
38. Polman Ch.H., Reingold S.C., Edan G., Filippi M., Hartung H.-P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple Sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
39. Ray A., LaForge S., Sehgal P.B. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticosteroids: enhancer, TATA box and RNA start site (Inr Motif) occlusion. Mol. Cell. Biol. 1990, 10:5736-5746.
40. Ristić S., Lovrecić L., Starcević-Cizmarević N., Brajenović-Milić B., Sega-Jazbec C., Sepcić J., Kapović M., Peterlin B. Tumor necrosis-alfa-308 gene polymorphism in Croatian and Slovenian multiple sclerosis patients. Eur. Neurol. 2007, 57:203-207.
41. Roxburgh R.H.S.R., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., Achiti I., Confavreux C., Coustans M., le Page E., Eden G., McDonnell G.V., Hawkins S., Trojano M., Liguori M., Cocco E., Marrosu M.G., Tesser F., Leone M.A., Weber A., Zipp F., Miterski B., Epplen J.T., Oturai A., Soelberg Sorensen P., Celius E.G., Téllez Lara N., Montalban X., Villoslada P., Silva A.M., Marta M., Leite I., Dubois B., Rubio J., Butzkueven H., Kilpatrick T., Mycko M.P., Selmaj K.W., Rio M.E., Sá M., Salemi G., Savettieri G., Hillert J., Compston D.A.S. Multiple sclerosis severity score. Using disability and disease duration to rate disease severity. Neurology 2005, 64:1144-1151.
42. Schönrock L.M., Gawlowski G., Brück W. Interleukin-6 expression in human multiple sclerosis lesions. Neurosci. Lett. 2000, 294:45-48.
43. Schrijver H.M., Crusius J.B., Uitdehaag B.M., Garcia-Gonzalez M.A., Kostense P.J., Polman C.H., Pena A.S. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology 1999, 52:595-599.
44. Schulte-Herbrüggen O., Nassenstein Ch., Lommatzsch M., Quarcoo D., Renz H., Braun A. Tumor necrosis factor-α and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 2005, 160:204-209.
45. Sciacca F.L., Ferri C., Vandenbroeck K., Veglia F., Gobbi C., Martinelli F., Franciotta D., Zaffaroni M., Marrosu M., Martino G., Martinelli V., Comi G., Canal N., Grimaldi L.M. Relevance of interleukin1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999, 52:1896-1898.
46. Seddon B., Mason D. Peripheral autoantigen induces regulatory T cells that prevent autoimmunity. J. Exp. Med. 1999, 189:877-882.
47. Selmaj K., Raine C., Canella B., Brosnan C. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 1991, 87:949-954.
48. Shahbazi M., Ebadi H., Fathi D., Roshandel D., Mohamadhosseni M., Tahmasebi A., Shahbazi S., Zamani M., Rashidbaghan A. HLA-DRB1*1501 intensifies the impact of IL-6 promoter polymorphism on the susceptibility to multiple sclerosis in an Iranian population. Mult. Scler. 2010, 16:1173-1176.
49. Woodroofe M.N., Cuzner M.L. Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 1993, 5:583-588.